News
FDA Authorizes Regeneron Monoclonal Antibodies for COVID-19
The U.S. FDA issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least...
News
Elsevier report highlights several new potential targets for pharmaceutical intervention to treat pancreatic cancer
Elsevier has published the findings of a new report on emerging trends in the pancreatic cancer literature. The report highlights several trending terms including XIST and linc00511. These long non-coding RNAs have the potential to not only be diagnostic/prognostic...
News
Fluvoxamine may prevent serious illness in COVID-19 patients
In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Medicine in St. Louis have found that the drug fluvoxamine seems to prevent some of...
News
Warren Buffett makes big investment in US pharmaceutical firms
The investment company run by billionaire investor Warren Buffett bet $5.7bn (£4.3bn) on pharmaceutical companies during the third quarter of 2020, as the sector takes centre stage in the fight against the coronavirus pandemic.
Berkshire Hathaway bought shares in drug...
News
Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise
Bristol Myers Squibb announced that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select...
News
Twin challenges for Indian pharma-boosting drug discovery and localising API production
India is often referred to as the ‘pharmacy of the world’; not without reason. The third largest pharmaceutical market in the world by volume, India supplies a bulk of generic drugs globally not just to under-developed countries but also...
Drug Research
Exeter University and Medicines Discovery Catapult collaborate on R&D drive
The collaboration will focus on identifying promising innovations that can be adopted through the industry in the ultimate hope of benefitting patients. The collaboration will combine the world-class research at the University of Exeter with MDC’s industry skills, discovery...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















